8 Stocks on Jim Cramer’s Radar

6. ADMA Biologics, Inc. (NASDAQ:ADMA)

Number of Hedge Fund Holders: 25

Cramer noted that ADMA Biologics, Inc. (NASDAQ:ADMA) has “earnings” and appreciated its plasma-derived therapeutics but advised to wait for the stock to come down.

“I, well, okay, so it does have earnings, which is a terrific difference. Not that much of a spec and it does great blood plasma work. My problem is, I don’t have a catalyst. I think the stock at 40 times earnings is a little too rich. I would wait for it to come down before I would pull the trigger.”

ADMA Biologics (NASDAQ:ADMA) is a biopharmaceutical company focused on developing and marketing plasma-derived biologics for treating immune deficiencies and infectious diseases, with products like BIVIGAM, ASCENIV, and Nabi-HB, along with a pipeline targeting S. pneumonia infections. Cramer was asked about the company in August 2024 and he noted that the stock is a spec as he commented:

“This is a very speculative situation…Any time there’s immunity compromised patients, there’s some big money down the road.”